NCT05723055View on ClinicalTrials.gov

Evaluating Combination of Nivolumab and Axatilimab in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

April 20, 2023

Primary Completion Date

May 31, 2026

Study Completion Date

April 30, 2028

Conditions
Hodgkin Lymphoma
Interventions
DRUG

Axatilimab

Axatilimab (SNDX-6352) is a humanized IgG4 monoclonal antibody (mAb) with high affinity against colony stimulating factor-1 receptor (CSF-1R).

DRUG

Nivolumab

Nivolumab is a programmed death receptor-1 (PD-1)-blocking antibody

Trial Locations (2)

48201

RECRUITING

Karmanos Cancer Institute, Detroit

84112

RECRUITING

Huntsman Cancer Institute at the University of Utah, Salt Lake City

Sponsors

Collaborators (1)

Incyte Corporation
All Listed Sponsors
collaborator

Incyte Corporation

INDUSTRY

lead

University of Utah

OTHER